The Asia Pacific Joint Pain Injections Market should witness market growth of 8.6% CAGR during the forecast period (2022-2028).
Injections are useful because they can momentarily lessen swelling and pain in inflamed joints. Therapeutic joint injections are minimally invasive, target the afflicted area directly, and provide localized relief with few to no adverse effects. Joint injections are frequently advised for patients seeking long-term relief from pain that does not improve with more traditional therapies, such as oral anti-inflammatory drugs. Most people have pain reduction after a peripheral intra-articular injection for two to six months.
Injections can reduce pain and inflammation to a sufficient degree to allow other treatments for the underlying problem to be used, even though they do not treat the condition that causes joint pain. Physical treatment helps strengthen muscles and improve mobility in the afflicted joint, enhancing the positive benefits of joint injections. Physical therapy sessions could be advised in addition to a period of joint rest. In order to enhance the biomechanics of a joint, patients may also be encouraged to undertake lifestyle adjustments, such as decreasing weight or switching up their footwear. The goal is to limit or eliminate the need for additional injections by including joint injections in a more comprehensive therapeutic strategy.
China has one of the world's fastest-aging populations. By 2040, 28% of the population of China is projected to be over 60 due to increased life expectancy and declining birth rates. This significant population change presents new opportunities and difficulties for socioeconomic growth and public health. Therefore, developing an integrated system that addresses the social and medical requirements of the elderly while guaranteeing universal access to healthcare, regardless of location, is particularly crucial. The prevalence of illnesses calling for joint pain injections may increase as the population becomes older. As a result, the Asia Pacific region's market for joint pain injections might expand.
The China market dominated the Asia Pacific Joint Pain Injections Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $717.6 Million by 2028. The Japan market is registering a CAGR of 7.9% during (2022-2028). Additionally, The India market would showcase a CAGR of 9.2% during (2022-2028).
Based on Injection Type, the market is segmented into Interleukin Inhibitors, Hyaluronic Acid Injections, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Joint Type Channel, the market is segmented into Knee & Ankle, Shoulder & Elbow, Hip Joint, Facet Joints of the Spine, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bioventus Inc., Pacira BioSciences, Inc., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc., Anika Therapeutics, Inc., Zimmer Biomet Holdings, Inc., Eli Lilly And Company, Ferring Holdings SA, and Sanofi S.A.
Injections are useful because they can momentarily lessen swelling and pain in inflamed joints. Therapeutic joint injections are minimally invasive, target the afflicted area directly, and provide localized relief with few to no adverse effects. Joint injections are frequently advised for patients seeking long-term relief from pain that does not improve with more traditional therapies, such as oral anti-inflammatory drugs. Most people have pain reduction after a peripheral intra-articular injection for two to six months.
Injections can reduce pain and inflammation to a sufficient degree to allow other treatments for the underlying problem to be used, even though they do not treat the condition that causes joint pain. Physical treatment helps strengthen muscles and improve mobility in the afflicted joint, enhancing the positive benefits of joint injections. Physical therapy sessions could be advised in addition to a period of joint rest. In order to enhance the biomechanics of a joint, patients may also be encouraged to undertake lifestyle adjustments, such as decreasing weight or switching up their footwear. The goal is to limit or eliminate the need for additional injections by including joint injections in a more comprehensive therapeutic strategy.
China has one of the world's fastest-aging populations. By 2040, 28% of the population of China is projected to be over 60 due to increased life expectancy and declining birth rates. This significant population change presents new opportunities and difficulties for socioeconomic growth and public health. Therefore, developing an integrated system that addresses the social and medical requirements of the elderly while guaranteeing universal access to healthcare, regardless of location, is particularly crucial. The prevalence of illnesses calling for joint pain injections may increase as the population becomes older. As a result, the Asia Pacific region's market for joint pain injections might expand.
The China market dominated the Asia Pacific Joint Pain Injections Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $717.6 Million by 2028. The Japan market is registering a CAGR of 7.9% during (2022-2028). Additionally, The India market would showcase a CAGR of 9.2% during (2022-2028).
Based on Injection Type, the market is segmented into Interleukin Inhibitors, Hyaluronic Acid Injections, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Joint Type Channel, the market is segmented into Knee & Ankle, Shoulder & Elbow, Hip Joint, Facet Joints of the Spine, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bioventus Inc., Pacira BioSciences, Inc., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc., Anika Therapeutics, Inc., Zimmer Biomet Holdings, Inc., Eli Lilly And Company, Ferring Holdings SA, and Sanofi S.A.
Scope of the Study
By Injection Type
- Interleukin Inhibitors
- Hyaluronic Acid Injections
- Others
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Others
By Joint Type
- Knee & Ankle
- Shoulder & Elbow
- Hip Joint
- Facet Joints of the Spine
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Bioventus Inc.
- Pacira BioSciences, Inc.
- AbbVie, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc.
- Anika Therapeutics, Inc.
- Zimmer Biomet Holdings, Inc.
- Eli Lilly And Company
- Ferring Holdings SA
- Sanofi S.A.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Joint Pain Injections Market, by Injection Type
1.4.2 Asia Pacific Joint Pain Injections Market, by Distribution Channel
1.4.3 Asia Pacific Joint Pain Injections Market, by Joint Type
1.4.4 Asia Pacific Joint Pain Injections Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Joint Pain Injections Market by Injection Type
3.1 Asia Pacific Interleukin Inhibitors Market by Country
3.2 Asia Pacific Hyaluronic Acid Injections Market by Country
3.3 Asia Pacific Others Market by Country
Chapter 4. Asia Pacific Joint Pain Injections Market by Distribution Channel
4.1 Asia Pacific Drug Stores & Retail Pharmacies Market by Country
4.2 Asia Pacific Hospital Pharmacies Market by Country
4.3 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Joint Pain Injections Market by Joint Type
5.1 Asia Pacific Knee & Ankle Market by Country
5.2 Asia Pacific Shoulder & Elbow Market by Country
5.3 Asia Pacific Hip Joint Market by Country
5.4 Asia Pacific Facet Joints of the Spine Market by Country
5.5 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Joint Pain Injections Market by Country
6.1 China Joint Pain Injections Market
6.1.1 China Joint Pain Injections Market by Injection Type
6.1.2 China Joint Pain Injections Market by Distribution Channel
6.1.3 China Joint Pain Injections Market by Joint Type
6.2 Japan Joint Pain Injections Market
6.2.1 Japan Joint Pain Injections Market by Injection Type
6.2.2 Japan Joint Pain Injections Market by Distribution Channel
6.2.3 Japan Joint Pain Injections Market by Joint Type
6.3 India Joint Pain Injections Market
6.3.1 India Joint Pain Injections Market by Injection Type
6.3.2 India Joint Pain Injections Market by Distribution Channel
6.3.3 India Joint Pain Injections Market by Joint Type
6.4 South Korea Joint Pain Injections Market
6.4.1 South Korea Joint Pain Injections Market by Injection Type
6.4.2 South Korea Joint Pain Injections Market by Distribution Channel
6.4.3 South Korea Joint Pain Injections Market by Joint Type
6.5 Singapore Joint Pain Injections Market
6.5.1 Singapore Joint Pain Injections Market by Injection Type
6.5.2 Singapore Joint Pain Injections Market by Distribution Channel
6.5.3 Singapore Joint Pain Injections Market by Joint Type
6.6 Malaysia Joint Pain Injections Market
6.6.1 Malaysia Joint Pain Injections Market by Injection Type
6.6.2 Malaysia Joint Pain Injections Market by Distribution Channel
6.6.3 Malaysia Joint Pain Injections Market by Joint Type
6.7 Rest of Asia Pacific Joint Pain Injections Market
6.7.1 Rest of Asia Pacific Joint Pain Injections Market by Injection Type
6.7.2 Rest of Asia Pacific Joint Pain Injections Market by Distribution Channel
6.7.3 Rest of Asia Pacific Joint Pain Injections Market by Joint Type
Chapter 7. Company Profiles
7.1 Bioventus Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Product Launches and Product Expansions:
7.2 Pacira BioSciences, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Research & Development Expenses
7.2.4 Recent strategies and developments:
7.2.4.1 Acquisition and Mergers:
7.3 AbbVie, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Trails and Approvals:
7.4 Teva Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.6 Anika Therapeutics, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Zimmer Biomet Holdings, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.8 Eli Lilly And Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.9 Ferring Holdings SA
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research and Development Expense
7.10. Sanofi S.A.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
Companies Mentioned
- Bioventus Inc.
- Pacira BioSciences, Inc.
- AbbVie, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc.
- Anika Therapeutics, Inc.
- Zimmer Biomet Holdings, Inc.
- Eli Lilly And Company
- Ferring Holdings SA
- Sanofi S.A.
Methodology
LOADING...
